Eun Yang
Stock Analyst at Jefferies
(0.67)
# 3,818
Out of 4,786 analysts
46
Total ratings
50%
Success rate
-14.15%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $308.27 | +40.14% | 8 | Sep 23, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | $65 → $2 | $2.51 | -20.32% | 3 | Jun 17, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $1.39 | +475.54% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $5.34 | +405.62% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.65 | +129.18% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $34.57 | -4.54% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $2.13 | +1,214.55% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $19.68 | +37.20% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.27 | +208.37% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $2.77 | - | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.99 | +1,156.28% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $75 | $0.87 | +8,493.03% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $84 | $88.51 | -5.10% | 3 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $0.98 | +2,451.28% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $4.57 | - | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $14.38 | +143.39% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $311.55 | -29.39% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $38 → $31 | $28.88 | +7.34% | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $136.84 | +126.54% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $112.05 | -28.60% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $308.27
Upside: +40.14%
Aerovate Therapeutics
Jun 17, 2024
Downgrades: Hold
Price Target: $65 → $2
Current: $2.51
Upside: -20.32%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $1.39
Upside: +475.54%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $5.34
Upside: +405.62%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.65
Upside: +129.18%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $34.57
Upside: -4.54%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $2.13
Upside: +1,214.55%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $19.68
Upside: +37.20%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.27
Upside: +208.37%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $2.77
Upside: -
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $1.99
Upside: +1,156.28%
Sep 22, 2022
Maintains: Buy
Price Target: $525 → $75
Current: $0.87
Upside: +8,493.03%
Aug 22, 2022
Maintains: Buy
Price Target: $78 → $84
Current: $88.51
Upside: -5.10%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $0.98
Upside: +2,451.28%
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $4.57
Upside: -
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $14.38
Upside: +143.39%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $311.55
Upside: -29.39%
Nov 3, 2017
Maintains: Hold
Price Target: $38 → $31
Current: $28.88
Upside: +7.34%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $136.84
Upside: +126.54%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $112.05
Upside: -28.60%